XTL Biopharmaceuticals Ltd.
XTLB
$1.31
$0.043.15%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 734.00K | 759.00K | 815.00K | 845.00K | 850.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 765.00K | 790.00K | 843.00K | 882.00K | 880.00K |
| Operating Income | -765.00K | -790.00K | -843.00K | -882.00K | -880.00K |
| Income Before Tax | -1.78M | -2.25M | -2.85M | -2.77M | -1.35M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.78 | -2.25 | -2.85 | -2.77 | -1.35 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.78M | -2.25M | -2.85M | -2.77M | -1.35M |
| EBIT | -765.00K | -790.00K | -843.00K | -882.00K | -880.00K |
| EBITDA | -764.20K | -789.20K | -842.20K | -881.20K | -879.20K |
| EPS Basic | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 2.18B | 2.18B | 2.18B | 2.18B | 2.18B |
| Average Diluted Shares Outstanding | 2.18B | 2.18B | 2.18B | 2.18B | 2.18B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |